| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Retrospective Study |
| Article Title |
Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wei Zhang, Yun-Fang Zhao, Fei-Fei Liang, Xiao-Xia Liu, Jiang-Hong Liu, Jian-Dong Hao, Shu-Qin Cheng and Yan-Feng Wu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Zhangjiakou Key R&D Program Projects |
2021108D |
|
| Corresponding Author |
Yan-Feng Wu, Assistant Professor, Department of geriatrics, Zhangjiakou First Hospital in Hebei Province, No. 6 Baisi Lane, Xinhua Front Street, Qiaoxi District,, Zhangjiakou 075000, Hebei Province, China. wuyanfeng1128@163.com |
| Key Words |
Anlotinib; Albumin paclitaxel; Clinical effect; Immune function; Quality of life; Mental state |
| Core Tip |
A study evaluated the efficacy of anlotinib combined with albumin paclitaxel for stage IV non-small cell lung cancer (NSCLC). Forty-two patients were split into two groups: One group received albumin paclitaxel (n = 20), and the other received anlotinib plus albumin paclitaxel (n = 22). The study compared clinical outcomes, tumor markers, progression-free survival, overall survival, immune function, quality of life, mental health, and side effects. The combination therapy group showed higher disease remission and control rates, better immune markers and quality of life scores, and lower tumor biomarkers and mental health scores. Adverse reactions were similar in both groups. The combination of anlotinib and albumin paclitaxel was effective in treating stage IV NSCLC, reducing depression and anxiety, lowering tumor biomarkers, enhancing immune function, prolonging survival, and improving quality of life. |
| Publish Date |
2025-08-08 10:23 |
| Citation |
<p>Zhang W, Zhao YF, Liang FF, Liu XX, Liu JH, Hao JD, Cheng SQ, Wu YF. Role of anlotinib plus albumin paclitaxel regimen in stage IV non-small cell lung cancer and mental state. <i>World J Psychiatry</i> 2025; 15(8): 103735</p> |
| URL |
https://www.wjgnet.com/2220-3206/full/v15/i8/103735.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v15.i8.103735 |
